Medline, the major player in the medical supplies industry, is gearing up for a significant initial public offering (IPO) in the United States, with a target valuation reaching as high as $55.3 billion. The Northfield, Illinois-based company aims to raise up to $5.37 billion by offering 179 million shares, priced between $26 and $30 each. As the IPO market approaches its final stretch for 2025, Medline’s listing is set to become one of the year’s most notable events.
Market analysts expect a flurry of activity in upcoming weeks as other companies also seek to capitalize on the limited window before the holiday slowdown. “Large deals tend to significantly influence IPO investor sentiment,” noted Matt Kennedy, a senior strategist at Renaissance Capital. He emphasized that Medline’s IPO could set the tone for both the remainder of the year and into 2026, although he cautioned that it may not be decisive for the broader listings market, which appears resilient going forward.
The anticipated IPO is crucial not only for Medline but also for the overall market, as it will test investor appetite outside of high-performing sectors like cryptocurrency, artificial intelligence, and fintech. Josef Schuster, CEO of IPOX, highlighted that the performance of Medline’s offering is critical as it seeks to rejuvenate interest in IPOs across varied industries.
If approved, Medline’s IPO would rank among the largest private equity-backed public offerings, surpassing the notable $4.35 billion IPO of HCA Holdings in 2011. The company, a significant manufacturer of surgical kits, gloves, and protective apparel, has a storied history, originally founded in 1966 by brothers James and Jon Mills. Medline transitioned from public to private ownership in 1977, only to be reacquired in 2021 for $34 billion by investment firms including Blackstone, Carlyle, and Hellman & Friedman.
Medline’s strong financial performance underlines its value proposition; the company reported a net income of $977 million for the first nine months of the fiscal year, up from $911 million in the previous year, with net sales climbing to $20.6 billion compared to $18.7 billion. However, the company anticipates a tax-related hit of $325 to $375 million in fiscal 2025 and between $150 to $200 million in fiscal 2026 due to tariffs.
In terms of investments, cornerstone investors have expressed interest in acquiring up to $2.35 billion worth of shares, with notable firms such as Baillie Gifford and Morgan Stanley’s Counterpoint Global among them. Additionally, members of the Mills family are reportedly looking to purchase up to $250 million of the shares in the offering.
The underwriting is being managed by a consortium of investment banks, including Goldman Sachs, Morgan Stanley, Bank of America Securities, and J.P. Morgan, with plans to list on the Nasdaq under the symbol “MDLN.” This impending IPO not only marks a significant financial moment for Medline but also serves as a barometer for investor confidence in the broader IPO market as 2025 draws to a close.
